USFDA Approved Latest Drug for Lung Cancer Patients
Beacon Pharmaceuticals Limited, the leading oncology company in Bangladesh, has introduced a groundbreaking treatment for lung cancer: Tagrix, the first global generic version of osimertinib.
Beacon Pharmaceuticals PLC is dedicated to developing high-quality, targeted medications to improve patient outcomes and address complex illnesses. Our mission is to promote global health by providing cost-effective healthcare solutions, and utilizing innovative & advanced manufacturing processes. We offer a wide range of products, including 200 general, and 70 oncology medications across Various therapeutic tic classes.